Ocugen (NASDAQ:OCGN) stock rose about 10% over the weekend. This comes after the company won U.S. Food and Drug Administration (FDA) clearance to advance its rare eye disease treatment to a Phase 3 trial.OCU400 is a gene therapy being developed for retinitis pigmentosa (RP). RP causes the retina at the back of the eye to break down over time, eventually resulting in blindness.Shares of OCGN are up more than 7% as of this writing, at around $1.90 per share and a market capitalization of roughly $485 million. ...

MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). "The initiati ...

Ocugen (NASDAQ: OCGN) stock price has been one of the best-performing companies in Wall Street this year. It has jumped by more than 218% in 2024, beating some of the best-known brands like Nvidia and Amazon. This surge has boosted its total market cap to over $469 million. Why Ocugen shares are soaring Copy link to section Ocugen became a highly popular company during the Covid-19 pandemic, thanks to its vaccine innovations. Its goal of becoming a major player in the vaccine industry failed amid rising com ...

Biotechnology firm Ocugen (NASDAQ:OCGN) — which specializes in developing gene therapies to address blindness diseases — saw its shares move higher on an encouraging clinical development. An advisory committee responsible for overseeing safety matters approved Ocugen to use a medium dosage of its retinal therapeutic. Subsequently, OCGN stock moved higher on the positive implications.According to the company’s press release, Ocugen received a green light from the Data and Safety Monitoring Board (DSMB) for t ...

Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and approved to p ...

Shares of once high-flying biotech company Ocugen (NASDAQ:OCGN) are seeing some selling pressure again today. At the time of writing, OCGN stock is down over 9% on a business update provided by the company.Ocugen noted that Phase 3 trials of its OCU400 gene therapy drug are expected to commence in April, and other positive designation-related news was put forward. However, in this release, the company also revealed it would need to restate some of its financial statements.The company noted that errors were ...

Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (RMAT) designation granted by FDA to OCU400 Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respectively MALVERN, Pa., April 02, 2024 (GLOBE NEWSWIR ...

Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical TrialDSMB Determination to Proceed with Medium Dose Cohort Dosing MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data Safety and Monitoring Board (DSMB) for the OCU410ST clinical trial recently convened and approved to proceed dosin ...

MALVERN, Pa., April 01, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to provide a business update with certain financials for the year ending December 31, 2023 at 8:30 a.m. ET on Tuesday, April 2, 2024. Ocugen will issue a pre-market earnings announcement on the same day. Attendees are ...

MALVERN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ:OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Dr. Huma Qamar as Chief Medical Officer (CMO). "I'm very pleased to name Dr. Qamar as the CMO at Ocugen," said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen. "This appointment recognizes her invaluable contributi ...